Ocrelizumab
OcrevusUniProt P11836 · 3D model
Drag to rotate. Scroll or pinch to zoom.
A lab-made antibody that targets and clears out CD20-marked immune cells, quieting the misdirected immune attacks behind multiple sclerosis.
How it works
Certain immune cells called B cells play a troublemaking role in multiple sclerosis, mistakenly contributing to attacks on the nervous system. Ocrelizumab is an engineered antibody that recognizes a marker on many B cells and flags them for destruction by the immune system itself. With fewer of these B cells around, there's less inflammation and fewer attacks on nerve tissue.
What it’s used for
Approved to treat multiple sclerosis — both the relapsing form and the primary progressive form, which steadily worsens over time — in adults, and also in adolescents 10 and older with the relapsing type.
- Mechanism
- CD20 antagonist (mAb)
- Drug class
- Monoclonal antibody
- Therapeutic area
- Neurology